Table 2.
Univariate analyses of the relationships between clinicopathologic factors and survival
| Parameters | N |
PFS |
OS |
|||||
|---|---|---|---|---|---|---|---|---|
| Months | χ2 | P | Months | χ2 | P | |||
|
Gender |
Male |
55 |
4.433 |
|
|
7.400 |
|
|
| |
Female |
10 |
6.200 |
0.609 |
0.435 |
10.200 |
0.340 |
0.560 |
|
Age |
≤50 |
22 |
4.000 |
|
|
5.867 |
|
|
| |
>50 |
43 |
5.833 |
3.934 |
0.047 |
8.067 |
0.113 |
0.736 |
|
HBsAg |
Positive |
55 |
4.433 |
|
|
6.467 |
|
|
| |
Negative |
10 |
5.833 |
0.516 |
0.472 |
8.800 |
3.608 |
0.057 |
|
AFP(IU/ml) |
≤400 |
31 |
7.000 |
|
|
11.133 |
|
|
| |
>400 |
34 |
4.233 |
3.016 |
0.082 |
5.200 |
5.236 |
0.022 |
|
Tumor number |
Single |
18 |
5.600 |
|
|
8.967 |
|
|
| |
>1 |
47 |
4.967 |
0.168 |
0.682 |
5.867 |
0.981 |
0.322 |
|
Tumor size(cm) |
≤5 |
12 |
7.300 |
|
|
29.267 |
|
|
| |
>5 |
53 |
4.367 |
3.792 |
0.051 |
5.867 |
9.834 |
0.002 |
| Differentiation |
High |
17 |
6.200 |
|
|
5.233 |
|
|
| |
Middle |
33 |
4.367 |
|
|
8.967 |
|
|
| |
Low |
15 |
4.000 |
3.630 |
0.163 |
5.667 |
3.097 |
0.213 |
|
Child-Pugh |
A |
59 |
5.600 |
|
|
8.067 |
|
|
| |
B |
6 |
4.967 |
0.599 |
0.439 |
3.600 |
1.980 |
0.159 |
|
BCLC |
B |
7 |
5.633 |
|
|
10.500 |
|
|
| |
C |
58 |
4.433 |
3.527 |
0.060 |
7.400 |
0.274 |
0.600 |
|
Hepatic cirrhosis |
Yes |
34 |
4.967 |
|
|
6.533 |
|
|
| |
No |
31 |
4.433 |
0.002 |
0.965 |
8.967 |
0.194 |
0.659 |
| Ascites |
Yes |
14 |
4.367 |
|
|
5.000 |
|
|
| |
No |
51 |
5.600 |
2.706 |
0.100 |
8.967 |
3.887 |
0.049 |
| Tumor thrombus |
Yes |
28 |
3.000 |
|
|
5.000 |
|
|
| |
No |
37 |
5.833 |
2.800 |
0.094 |
11.367 |
8.067 |
0.005 |
|
Extrahepatic metastasis |
Yes |
41 |
4.367 |
|
|
6.467 |
|
|
| No | 24 | 5.600 | 0.878 | 0.349 | 8.967 | 0.017 | 0.897 | |
PFS, progression-free survival; OS, overall survival; HbsAg, hepatitis B surface antigen; AFP, serum alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer stage.